5-(2-氟苯基)吡咯烷-2-酮 | 1314714-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 5-(2-氟苯基)吡咯烷-2-酮
• 英文名称: 5-(2-fluorophenyl)pyrrolidin-2-one
• 英文别名: 5-(2-Fluorophenyl)pyrrolidin-2-one
• CAS: 1314714-04-9
• 化学式: C₁₀H₁₀FNO
• 分子量: 179.194
• InChiKey: XDJOUNUPRWGNRA-UHFFFAOYSA-N

物化性质

• 沸点：
  336.9±42.0 °C(Predicted)
• 密度：
  1?+-.0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-iodo-N-(quinolin-8-yl)benzamide 、 5-(2-氟苯基)吡咯烷-2-酮 在 copper(l) iodide 、 caesium carbonate 、 N,N'-二甲基乙二胺 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以29 mg的产率得到4-[2-(2-fluorophenyl)-5-oxopyrrolidin-1-yl]-N-quinolin-8-ylbenzamide
  参考文献：
  名称：

  Discovery of Novel, Induced-Pocket Binding Oxazolidinones as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors

  摘要：

  Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates beta-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of beta-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).

  DOI：

  10.1021/jm4000038
• 作为产物：
  描述：

  4-(2-氟苯基)-4-氧代丁酸乙酯 在 ammonium acetate 、 sodium cyanoborohydride 作用下， 以 甲醇 为溶剂， 生成 5-(2-氟苯基)吡咯烷-2-酮
  参考文献：
  名称：

  [EN] RIPK1 INHIBITORS AND METHODS OF USE
  [FR] INHIBITEURS DE RIPK1 ET PROCÉDÉS D'UTILISATION

  摘要：

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

  公开号：

  WO2023225041A1

文献信息

• SUBSTITUTED PYRROLIDINE AMIDES II
  申请人：Grünenthal GmbH

  公开号：EP3728233B1

  公开（公告）日：2022-04-20
• Discovery of Novel, Induced-Pocket Binding Oxazolidinones as Potent, Selective, and Orally Bioavailable Tankyrase Inhibitors
  作者：Howard Bregman、Nagasree Chakka、Angel Guzman-Perez、Hakan Gunaydin、Yan Gu、Xin Huang、Virginia Berry、Jingzhou Liu、Yohannes Teffera、Liyue Huang、Bryan Egge、Erin L. Mullady、Steve Schneider、Paul S. Andrews、Ankita Mishra、John Newcomb、Randy Serafino、Craig A. Strathdee、Susan M. Turci、Cindy Wilson、Erin F. DiMauro

  DOI：10.1021/jm4000038

  日期：2013.6.13

  Tankyrase (TNKS) is a poly-ADP-ribosylating protein (PARP) whose activity suppresses cellular axin protein levels and elevates beta-catenin concentrations, resulting in increased oncogene expression. The inhibition of tankyrase (TNKS1 and 2) may reduce the levels of beta-catenin-mediated transcription and inhibit tumorigenesis. Compound 1 is a previously described moderately potent tankyrase inhibitor that suffers from poor pharmacokinetic properties. Herein, we describe the utilization of structure-based design and molecular modeling toward novel, potent, and selective tankyrase inhibitors with improved pharmacokinetic properties (39, 40).
• [EN] RIPK1 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE RIPK1 ET PROCÉDÉS D'UTILISATION
  申请人：[en]MERCK SHARP & DOHME LLC

  公开号：WO2023225041A1

  公开（公告）日：2023-11-23

  Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.